OSE Immunotherapeutics: Funding, Investors & Team (Sep 2026)
OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.
OSE Immunotherapeutics has raised $24.9M across 2 funding rounds on record, the most recent a Debt Financing of $11.9M announced in Jul 2021.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OSE Immunotherapeutics Company Profile and Key Stats
Latest funding round on record: Jul 2021.
OSE Immunotherapeutics Funding Rounds
OSE Immunotherapeutics raised $13.0M in an undisclosed round announced in May 2021.
2 months later, a Debt Financing of $11.9M was announced in Jul 2021.
OSE Immunotherapeutics Founders and Leadership Team
Contact details for the OSE Immunotherapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →OSE Immunotherapeutics Funding Compared to Other Biotechnology Startups
OSE Immunotherapeutics' latest round of $11.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OSE Immunotherapeutics in Biotechnology and Nantes
Companies Similar to OSE Immunotherapeutics
Brenus Pharma is a platform that uses allogeneic techniques to create immune therapy with the goal of…
TISSIUM is a privately owned medical device company based in Paris, France that is dedicated to the rapid…
NicOx is a biopharmaceutical company that focuses on creating and selling nitric oxide-donating drugs for…
Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from…
One Biosciences was founded in Paris, Ile-de-France, France by Magali Richard, David Schilansky, and Céline…
Inventiva Pharma is a biopharmaceutical company in the clinical stage that focuses on creating oral small…
NETRIS Pharma develops therapeutic molecules for treating cancer by targeting dependence receptors for the…
AbIONYX Pharma is a biotechnology company that is focused on providing innovative therapies for indications…
Founded in 2003, Nanobiotix is at the forefront of nanomedicine and is committed to revolutionizing patient…
Theraclion specializes in high-tech medical equipment using high-intensity focused ultrasound (HIFU). They…
Abivax, a clinical stage biotechnology company, is mobilizing the body’s natural immune machinery to treat…
AB Science was established in 2001 by a group of individuals in the medical and business fields who are…
OSE Immunotherapeutics Funding FAQs
What does OSE Immunotherapeutics do?
OSE Immunotherapeutics is a biotechnology company led by world-class immunologists and focused on the development of innovative immunotherapies for immune activation and regulation in the fields of immuno-oncology, auto-immune diseases and transplantation.
How much funding has OSE Immunotherapeutics raised?
OSE Immunotherapeutics has raised $24.9M across 2 rounds on record. The most recent is a Debt Financing of $11.9M announced in Jul 2021.
When did OSE Immunotherapeutics last raise funding?
OSE Immunotherapeutics' most recent funding round on record is a Debt Financing of $11.9M, announced in Jul 2021.
Who is the CEO of OSE Immunotherapeutics?
Alexis Peyroles is listed as CEO at OSE Immunotherapeutics.
Where is OSE Immunotherapeutics headquartered?
OSE Immunotherapeutics is based in Nantes, Pays De La Loire, France.
How many employees does OSE Immunotherapeutics have?
OSE Immunotherapeutics is in the 51-100 employee band.
How does OSE Immunotherapeutics' funding compare to other Biotechnology startups?
OSE Immunotherapeutics' latest round of $11.9M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's OSE Immunotherapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OSE Immunotherapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.